Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$17.06M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
182.11%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$3.352M
Q3 2024
Cash
Q3 2024
P/E
-0.3660
Nov 29, 2024 EST
Free Cash Flow
-$9.338M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $4.770M $5.967M $4.681M $4.390M $1.980M $860.0K $180.0K
YoY Change -20.07% 27.48% 6.63% 121.72% 130.23% 377.78%
% of Gross Profit
Research & Development $14.10M $9.300M $9.346M $5.060M $1.850M $20.00K $30.00K
YoY Change 51.56% -0.5% 84.71% 173.51% 9150.0% -33.33%
% of Gross Profit
Depreciation & Amortization $4.130K $11.76K $13.07K $10.00K $0.00
YoY Change -64.87% -10.05% 30.7%
% of Gross Profit
Operating Expenses $18.87M $15.27M $14.03M $9.450M $3.830M $880.0K $220.0K
YoY Change 23.57% 8.84% 48.44% 146.74% 335.23% 300.0%
Operating Profit -$18.87M -$15.27M -$14.49M
YoY Change 23.57% 5.39%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $13.88K $7.027K -$9.290K $0.00 -$40.00K -$50.00K $0.00
YoY Change 97.52% -175.64% -100.0% -20.0%
% of Operating Profit
Other Income/Expense, Net $13.88K -$7.027K -$9.285K $0.00 -$180.0K $0.00
YoY Change -297.55% -24.32% -100.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$18.85M -$15.27M -$14.04M -$9.460M -$3.880M -$7.390M -$220.0K
YoY Change 23.42% 8.82% 48.38% 143.81% -47.5% 3259.09%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.85M -$15.27M -$14.04M -$9.460M -$3.880M -$7.390M -$220.0K
YoY Change 23.42% 8.82% 48.38% 143.81% -47.5% 3259.09%
Net Earnings / Revenue
Basic Earnings Per Share -$5.00 -$11.22 -$16.50
Diluted Earnings Per Share -$5.00 -$11.22 -$532.6K -$569.2K -$284.2K -$470.4K -$14.00K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $548.7K $10.06M $5.005M $14.04M $7.240M $280.0K $110.0K
YoY Change -94.54% 100.93% -64.36% 93.92% 2485.71% 154.55%
Cash & Equivalents $548.7K $10.06M $5.005M $14.04M $7.240M $280.0K $110.0K
Short-Term Investments
Other Short-Term Assets $1.042M $2.509M $2.473M $1.460M $650.0K $300.0K $50.00K
YoY Change -58.46% 1.47% 69.38% 124.62% 116.67% 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.591M $12.56M $7.477M $15.50M $7.890M $590.0K $160.0K
YoY Change -87.34% 68.03% -51.76% 96.45% 1237.29% 268.75%
Property, Plant & Equipment $4.930K $5.660K $16.11K $20.00K $20.00K
YoY Change -12.9% -64.87% -19.45% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $104.8K $482.8K $1.264M $330.0K $0.00 $100.0K $0.00
YoY Change -78.3% -61.8% 282.98% -100.0%
Total Long-Term Assets $109.7K $488.5K $1.280M $350.0K $20.00K $90.00K $0.00
YoY Change -77.55% -61.84% 265.7% 1650.0% -77.78%
Total Assets $1.701M $13.05M $8.757M $15.85M $7.910M $680.0K $160.0K
YoY Change
Accounts Payable $5.832M $3.682M $1.523M $950.0K $240.0K $130.0K $40.00K
YoY Change 58.4% 141.78% 60.3% 295.83% 84.62% 225.0%
Accrued Expenses $828.4K $225.0K $520.0K $20.00K $20.00K $40.00K
YoY Change 268.26% -56.74% 2500.0% 0.0% -50.0%
Deferred Revenue
YoY Change
Short-Term Debt $300.8K $410.0K $387.8K $440.0K $0.00 $320.0K $120.0K
YoY Change -26.63% 5.72% -11.87% -100.0% 166.67%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.133M $4.920M $2.136M $1.910M $310.0K $1.230M $220.0K
YoY Change 24.65% 130.4% 11.81% 516.13% -74.8% 459.09%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Total Liabilities $6.133M $4.920M $2.136M $1.910M $310.0K $1.230M $220.0K
YoY Change 24.65% 130.4% 11.81% 516.13% -74.8% 459.09%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 3.767M shares 1.362M shares 878.4K shares
Diluted Shares Outstanding 3.767M shares 1.362M shares 878.4K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $6.2431 Million

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Houston, Texas and currently employs 3 full-time employees. The company went IPO on 2019-11-08. CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The firm's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The firm is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Industry: Pharmaceutical Preparations Peers: CLS Holdings USA, Inc. Emmaus Life Sciences, Inc. Enveric Biosciences, Inc. AmeriCann, Inc. ARTELO BIOSCIENCES, INC. Can B Corp JOHNSON & JOHNSON RANGE IMPACT, INC. PALISADE BIO, INC.